HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mooradian, A. D. Articles by Wong, N. C.W. Search for Related Content PubMed PubMed Citation Articles by Mooradian, A. D. Articles by Wong, N. C.W. Social Bookmarking                What's this?

Transcriptional Control of Apolipoprotein A-I Gene Expression in Diabetes

¹ Division of Endocrinology, Diabetes and Metabolism, Department of Internal Medicine, Saint Louis University School of Medicine, Saint Louis, Missouri
² Department of Medicine and Biochemistry & Molecular Biology, University of Calgary, Alberta, Canada

Cardiovascular disease continues to be the leading cause of mortality in diabetes. One of the factors contributing to the increased risk is the high prevalence rate of low plasma concentrations of HDL cholesterol. Multiple potential mechanisms account for the cardioprotective effects of HDL and its main protein apolipoprotein (apo) A-I. The reduced plasma concentrations of HDL could be the result of increased fractional clearance of HDL and reduced expression of apo A-I. In animal models of diabetes and in cell cultures treated with high concentrations of glucose, apo A-I expression is reduced. In this review we will discuss the alterations in transcriptional control of apo A-I in diabetes. The role of select nutritional and hormonal alterations commonly found in diabetes will be reviewed. Specifically, we will review the literature on the effect of hyperglycemia, hypoinsulinemia, and ketoacidosis, as well as the role of various mediators of insulin resistance, such as fatty acids, cytokines, and prostanoids, on apo A-I promoter activity. Identifying the mechanisms that modulate apo A-I gene expression will aid in the new development of therapeutic agents that increase plasma apo A-I and HDL concentrations.

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				S. G. Albert, R. Fishman Oiknine, S. Parseghian, A. D. Mooradian, M. J. Haas, and T. McPherson The Effect of Glucosamine on Serum HDL Cholesterol and Apolipoprotein AI Levels in People With Diabetes Diabetes Care, November 1, 2007; 30(11): 2800 - 2803. [Abstract] [Full Text] [PDF]

				L.-W. Chang, B. R. Fontaine, G. D. Stormo, and R. Nagarajan PAP: a comprehensive workbench for mammalian transcriptional regulatory sequence analysis Nucleic Acids Res., July 13, 2007; 35(suppl_2): W238 - W244. [Abstract] [Full Text] [PDF]

				X.-L. Zheng and N. C W Wong Cyclosporin A inhibits apolipoprotein AI gene expression. J. Mol. Endocrinol., October 1, 2006; 37(2): 367 - 373. [Abstract] [Full Text] [PDF]

				D. Rothenbacher, H. Brenner, W. Marz, and W. Koenig Adiponectin, risk of coronary heart disease and correlations with cardiovascular risk markers Eur. Heart J., August 2, 2005; 26(16): 1640 - 1646. [Abstract] [Full Text] [PDF]

				P. Dandona, A. Aljada, A. Chaudhuri, P. Mohanty, and R. Garg Metabolic Syndrome: A Comprehensive Perspective Based on Interactions Between Obesity, Diabetes, and Inflammation Circulation, March 22, 2005; 111(11): 1448 - 1454. [Full Text] [PDF]